RxDoctor Payments Data

Darrell Evans

Optometrist · Kingston, PANPI 1033149331

Payments from drug & device makers

$4,478in general payments, 2019–2025

Across 94 payments — averaging $47.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Bausch & Lomb Americas Inc.$504
  • Johnson & Johnson Vision Care, Inc.$462
  • Coopervision Inc.$355
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$212
  • AbbVie$157
  • plus $850 from 9 others

What the payments were for

  • Travel & lodging$72116%
  • Food & beverage$3,75784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,478 in reported general payments places this provider in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

See all optometrist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$188,153
Medicare patients
1,052
Services billed
2,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast35$34,997
RestasisCyclosporine28$24,165
LumiganBimatoprost55$21,327
Cyclosporine24$10,346
Timolol Maleate71$5,031
Latanoprost397$5,022
RocklatanNetarsudil Mesylat/Latanoprost11$3,713
Travoprost17$3,336
Brimonidine Tartrate11$2,968
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,892
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$829
Doxycycline Hyclate21$753
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha43$569
ErythromycinErythromycin Base35$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$157$45,49283 claims
Bausch & Lomb Americas Inc.Xiidra$504$34,99735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,165 optometrist providers in Pennsylvania.

Other optometrist in Kingston

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →